2007
CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
Kaufman P, Broadwater G, Lezon-Geyda K, Dressler L, Berry D, Friedman P, Winer E, Hudis C, Ellis M, Seidman A, Harris L. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). Journal Of Clinical Oncology 2007, 25: 1009-1009. DOI: 10.1200/jco.2007.25.18_suppl.1009.Peer-Reviewed Original Research
2006
Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study
Burstein H, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom P, Gelman R, Winer E. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. Journal Of Clinical Oncology 2006, 24: 650-650. DOI: 10.1200/jco.2006.24.18_suppl.650.Peer-Reviewed Original ResearchMetastatic breast cancerAdvanced breast cancerBreast cancerTaxane chemotherapyResponse rateMore frequent grade 3Stage IV breast cancerComparable clinical activityFrequent grade 3Protocol-based therapySide effect profileHigh response rateDose delaysEligible patientsMeasurable diseasePrior chemotherapyVinorelbine therapyWeekly taxanesWeekly vinorelbineChemotherapy regimenPrimary endpointTaxane therapyHematological toxicityEffect profileClinical trials
2002
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Seminars In Oncology 2002, 29: 38-43. PMID: 12138396, DOI: 10.1053/sonc.2002.34054.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHER2-overexpressing metastatic breast cancerUse of trastuzumabBreast cancerRandomized phase III clinical trialsHER2-overexpressing breast cancerPhase III clinical trialsHER2/neu proteinAdvanced breast cancerFirst-line treatmentForm of chemotherapyHumanized monoclonal antibodyLonger survival durationHigh response rateNew chemotherapy drugsAdjuvant settingChemotherapy combinationsSurvival durationClinical trialsFurther trialsEfficacious treatmentPlatinum agentsSingle agentUS FoodDrug AdministrationTrastuzumab/chemotherapy combinations in metastatic breast cancer
Ligibel J, Winer E. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Seminars In Oncology 2002, 29: 38-43. DOI: 10.1016/s0093-7754(02)70125-5.Peer-Reviewed Original ResearchMetastatic breast cancerHER2-overexpressing metastatic breast cancerUse of trastuzumabBreast cancerRandomized phase III clinical trialsHER2-overexpressing breast cancerPhase III clinical trialsHER2/neu proteinAdvanced breast cancerFirst-line treatmentForm of chemotherapyHumanized monoclonal antibodyLonger survival durationHigh response rateNew chemotherapy drugsAdjuvant settingChemotherapy combinationsSurvival durationClinical trialsFurther trialsEfficacious treatmentPlatinum agentsSingle agentUS FoodDrug Administration
2001
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Burstein H, Kuter I, Campos S, Gelman R, Tribou L, Parker L, Manola J, Younger J, Matulonis U, Bunnell C, Partridge A, Richardson P, Clarke K, Shulman L, Winer E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal Of Clinical Oncology 2001, 19: 2722-30. PMID: 11352965, DOI: 10.1200/jco.2001.19.10.2722.Peer-Reviewed Original ResearchConceptsGrade 2 cardiac toxicityAdvanced breast cancerBreast cancerResponse rateCardiac toxicityHER2-overexpressing metastatic breast cancerOnly grade 4 toxicityHER2-positive breast cancerCumulative doxorubicin doseGrade 4 toxicityStudy of trastuzumabSymptomatic heart failureThird-line therapyFirst-line therapyType of chemotherapyMetastatic breast cancerPercent of womenHigh response rateConcurrent trastuzumabPrior chemotherapyWeekly vinorelbineMetastatic diseasePositive patientsHeart failureDoxorubicin dose